MIV 711

Drug Profile

MIV 711

Alternative Names: MIV-711

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Medivir AB
  • Class Antineoplastics; Osteoporosis therapies; Small molecules
  • Mechanism of Action Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • No development reported Bone metastases; Osteoporosis

Most Recent Events

  • 08 Dec 2016 An independent Data Monitoring Committee recommends continuation of the MIV-711-201 phase IIa study in Osteoarthritis
  • 27 Oct 2016 Medivir completes enrolment in its phase IIb trial for Osteoarthritis in Bulgaria, Georgia, Germany, Moldova, Romania and United Kingdom (NCT02705625)
  • 23 Sep 2016 Data Monitoring Committee recommends continuation of phase IIa study of MIV 711 in Osteoarthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top